[go: up one dir, main page]

AR056964A1 - Derivados de aminosulfonilo, composiciones farmaceuticas y sus usos - Google Patents

Derivados de aminosulfonilo, composiciones farmaceuticas y sus usos

Info

Publication number
AR056964A1
AR056964A1 ARP060101365A ARP060101365A AR056964A1 AR 056964 A1 AR056964 A1 AR 056964A1 AR P060101365 A ARP060101365 A AR P060101365A AR P060101365 A ARP060101365 A AR P060101365A AR 056964 A1 AR056964 A1 AR 056964A1
Authority
AR
Argentina
Prior art keywords
group
members
alkyl
groups
independently selected
Prior art date
Application number
ARP060101365A
Other languages
English (en)
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of AR056964A1 publication Critical patent/AR056964A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/76—Nitrogen atoms to which a second hetero atom is attached
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/84—Nitriles
    • C07D213/85—Nitriles in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se refiere a composiciones que comprenden los compuestos de formula (1) y a procedimientos de tratamiento de una afeccion que está mediada por la modulacion de la enzima 11-beta-hsd-1. Reivindicacion 1: Un compuesto de formula (1), en la que: R1 es 2-piridinilo que está sustituido o condensado con 1-3 grupos R6, con al menos un grupo R6 que está en la posicion 6' del piridinilo; b es 2; R2 y R3 se toman junto con el átomo de nitrogeno al que están unidos para formar un heterociclilo (4 a 11) miembros, y puede estar opcionalmente sustituido por 1 a 3 R6 grupos; los átomos de carbono de R1, R2, y R3 puede cada uno de ellos opcionalmente estar opcionalmente sustituido por 1 a 3 grupos R6; cada gruposR6 se selecciona independientemente entre el grupo constituido por halo, ciano, nitro, -CF3, -CHF2, -CH2F, trifluorometoxi, azido, hidroxi, alcoxi C1-6, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, -(CR7R8)v(ariloC6-12), -(CR7R8)vheterociclilo de (4 a 11) miembros, -(C=O)-R9, -(C=O)- O-R9, -O-(C=O)-R9, -R9-(C=O)-O-R10, -(CR9R10)q(C=O)(CR11R12)v(ariloC6-12), -(CR9R10)q(C=O)(CR11R12)vheterociclilo de (4 a 11) miembros, -O-(C=O)-NR13R14, -NR13(C=O)-R14, -(C=O)-NR13R14, -R13-(C=O)-NR14R15, -NR13R14, -NR13OR14, -S(O)kNR13R14, - S(O)jalquiloC1-6, -O-SO2-R15, -NR15-S(O)k-R16, -(CR17R18)qS(O)j(CR19R20)v(ariloC6-12), -(CR17R18)qS(O)j(CR19R20)vheterociclilo de (4 a 11) miembros, -(CR17R18)vO(CR19R20)q(ariloC6-12), y -(CR17R18)vO(CR19R20)qheterociclilo de (4 a 11) miembros; k se selecciona entre 1 y 2; j se selecciona entre el grupo constituido por 0, 1, y 2; t, u, p, q, y v son cada uno de ellos, se selecciona independientemente entre 0, 1 , 2, 3, 4, y 5; cualquiera átomos de carbono 1 o 2 de cualquiera grupos heterociclilo de (4 a 11) miembros puede estar opcionalmente sustituido con un oxo (=O); cualquier alquilo C1-6, cualquier arilo C6-12, y cualquier heterociclilo de (4 a 11) miembros de los grupos anteriores R6 puede estar opcionalmente sustituido con 1 a 3 sustituyentes seleccionados independientemente entre el grupo constituido por halo, ciano, nitro, -CF3, -CFH2, -CF2H, trifluorometoxi, azido, -OR21, -(C=O)-R21, -(C=O)-O-R21, -(C=O)-O-R21, --O-(C=O)-R21, -NR21(C=O)-R22, -(C=O)-NR21R22, - NR21R22, -NR21OR22, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, -(CR21R22)u(ariloC6-12), y -(CR21R22)uheterociclilo de (4 a 11) miembros; cada grupo R7, R8, R9, R10, R11, R12, R13, R14, R15, R16 , R17 , R18, R19, R20, R21, y R22 se selecciona independientemente entre el grupo constituido por H, alquilo C1-6, -(C=O)NalquiloC1-6, -(CR23R24)p(ariloC6-12), y -(CR23R24)pheterociclilo de (4 a 11) miembros; cualquiera de los 1 o 2 átomos de carbono del heterociclilo de (4 a 11) miembros de cada uno de estos grupos R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17, R18, R19, R20, R21, y R22 puede estar opcionalmente sustituido con un oxo (=O); cada R23 y R24 se selecciona independientemente entre H y alquilo C1-6; y en la que cualquiera de los sustituyentes mencionados anteriormente que comprende un grupo -CH3 (metilo), -CH2 (metileno), o -CH (metilo) que no está unido a un grupo halo, -SO o -SO2 o a un átomo de N, O o S opcionalmente lleva sobre dicho grupo un sustituyente seleccionado independientemente entre el grupo constituido por hidroxi, halo, alquilo C1-6, alcoxi C1-6, -NH2, -NHalquiloC1-6 y -N(alquiloC1-6)2; con la condicion de que -NR2R3 no sea un grupo no sustituido seleccionado entre el grupo de formulas (2) a (4), y con la condicional adicional de que cuando -R1 sea un grupo de formulas (4) o (5), entonces -NR2R3 no es un grupo no sustituido o sustituido, condensado o no condensado seleccionado entre el grupo de formulas (6) a (11); o una sal o solvato farmacéuticamente aceptable del mismo.
ARP060101365A 2005-04-07 2006-04-06 Derivados de aminosulfonilo, composiciones farmaceuticas y sus usos AR056964A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66961305P 2005-04-07 2005-04-07
US77249506P 2006-02-10 2006-02-10

Publications (1)

Publication Number Publication Date
AR056964A1 true AR056964A1 (es) 2007-11-07

Family

ID=36659708

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060101365A AR056964A1 (es) 2005-04-07 2006-04-06 Derivados de aminosulfonilo, composiciones farmaceuticas y sus usos

Country Status (8)

Country Link
US (1) US20070027118A1 (es)
AR (1) AR056964A1 (es)
GT (1) GT200600134A (es)
NL (1) NL1031532C2 (es)
PE (1) PE20061357A1 (es)
TW (1) TW200718424A (es)
UY (1) UY29457A1 (es)
WO (1) WO2006106423A2 (es)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005286793A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-CoA desaturase enzymes
CN101084212A (zh) 2004-09-20 2007-12-05 泽农医药公司 杂环衍生物及其作为硬脂酰CoA去饱和酶介导剂的用途
US7777036B2 (en) 2004-09-20 2010-08-17 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as therapeutic agents
MX2007003325A (es) 2004-09-20 2007-06-05 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores estearoil-coa-desaturasa.
EP2316458A1 (en) 2004-09-20 2011-05-04 Xenon Pharmaceuticals Inc. Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase
AU2005286648A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
CN101083993A (zh) 2004-09-20 2007-12-05 泽农医药公司 杂环衍生物及其作为硬脂酰CoA去饱和酶抑制剂的用途
BRPI0611187A2 (pt) 2005-06-03 2010-08-24 Xenon Pharmaceuticals Inc derivados aminotiazàis como inibidores da estearoil-coa desaturase humana
AR057570A1 (es) * 2005-11-14 2007-12-05 Solvay Pharm Gmbh Derivados de n-sulfamoil-n'-benzopiranopiperidinas espirocondensadas, composiciones farmaceuticas que los comprenden, un procedimiento para su preparacion y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por las isoenzimas anhidrasas carbonicas subtipos ii y/o
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
AU2007283113A1 (en) 2006-08-08 2008-02-14 Sanofi-Aventis Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for preparing them, medicaments comprising these compounds, and their use
TW200827346A (en) 2006-11-03 2008-07-01 Astrazeneca Ab Chemical compounds
TW200836719A (en) 2007-02-12 2008-09-16 Astrazeneca Ab Chemical compounds
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
JP2011500820A (ja) * 2007-10-25 2011-01-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｂ２受容体を制御するジアゼパン化合物
CN101597278B (zh) 2008-06-04 2013-04-17 中国中化股份有限公司 酰胺类化合物及其制备与应用
EP2310372B1 (en) 2008-07-09 2012-05-23 Sanofi Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
AU2009287118B9 (en) * 2008-09-01 2014-08-07 Merck Patent Gmbh Fused pyrrolidino-cyclopropane derivatives as selective 11-beta-hydroxysteroid dehydrogenase type 1 inhibitors
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
ES2350077B1 (es) 2009-06-04 2011-11-04 Laboratorios Salvat, S.A. Compuestos inhibidores de 11beta-hidroxiesteroide deshidrogenasa de tipo 1.
ES2443016T3 (es) 2009-08-26 2014-02-17 Sanofi Nuevos hidratos cristalinos de fluoroglicósidos heteroaromáticos, productos farmacéuticos que comprenden estos compuestos, y su empleo
US10268805B2 (en) * 2010-01-26 2019-04-23 At&T Intellectual Property I, L.P. System and method for providing multimedia digital rights transfer
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
US20120122928A1 (en) 2010-08-11 2012-05-17 Bayer Cropscience Ag Heteroarylpiperidine and -Piperazine Derivatives as Fungicides
US8759527B2 (en) 2010-08-25 2014-06-24 Bayer Cropscience Ag Heteroarylpiperidine and -piperazine derivatives as fungicides
EP2423210A1 (de) 2010-08-25 2012-02-29 Bayer CropScience AG Heteroarylpiperidin- und -piperazinderivate als Fungizide
CN107033139B (zh) 2010-10-27 2019-11-19 拜耳知识产权有限责任公司 作为杀真菌剂的杂芳基哌啶和杂芳基哌嗪衍生物
WO2012077655A1 (ja) * 2010-12-07 2012-06-14 塩野義製薬株式会社 Ｇｐｒ１１９アゴニスト活性を有するスピロ誘導体
MX352307B (es) 2011-02-01 2017-11-17 Bayer Ip Gmbh Derivados de heteroarilpiperidina y -piperazina como fungicidas.
EP2683700B1 (de) 2011-03-08 2015-02-18 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683705B1 (de) 2011-03-08 2015-04-22 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
DK2921491T3 (da) 2011-12-27 2017-11-27 Bayer Ip Gmbh Mellemforbindelser til fremstilling af heteroarylpiperidiner og ¿piperazinderivater som fungicider
LT2825541T (lt) 2012-03-16 2016-12-27 Vitae Pharmaceuticals, Inc. Kepenų x receptoriaus moduliatoriai
CA2865639C (en) 2012-03-16 2020-12-22 Vitae Pharmaceuticals, Inc. Liver x receptor modulators
CA2923735A1 (en) * 2013-09-16 2015-03-19 The Electric Fan Company Distributed, unfolding, embedded transaction and inventory apparatuses, methods and systems
CR20170392A (es) * 2015-03-02 2018-02-20 Amgen Inc Compuestos bicíclicos de sulfonamida cetona
TW201811766A (zh) 2016-08-29 2018-04-01 瑞士商諾華公司 N-(吡啶-2-基)吡啶-磺醯胺衍生物及其用於疾病治療之用途
CN116754695B (zh) * 2023-08-17 2023-11-03 长沙晨辰医药科技有限公司 一种异氰酸氯磺酰酯的衍生化检测方法
WO2025117672A1 (en) * 2023-12-01 2025-06-05 Hotspot Therapeutics, Inc. Indazolyl-piperidine sulfonamides and related compounds and their use in therapy

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2187767A1 (en) * 1994-04-14 1995-10-26 Joel R. Huff Alpha1c adrenergic receptor antagonists
CO5261615A1 (es) * 1999-12-01 2003-03-31 Agouron Pharma Compuestos, composiciones y metodos para estimular el crecimiento y elongacion de neuronas
TW200403058A (en) * 2002-04-19 2004-03-01 Bristol Myers Squibb Co Heterocyclo inhibitors of potassium channel function
ES2316964T3 (es) * 2003-02-24 2009-04-16 Arena Pharmaceuticals, Inc. Fenil-y piridilpipereidinia-derivados como moduladores del metabolismo de la glucosa.
EA200600990A1 (ru) * 2003-12-19 2006-10-27 Пфайзер Инк. Производные бензосульфониламинопиридин-2-ила и родственные соединения в качестве ингибиторов 11-бета-гидроксистероид-дегидрогеназы 1 типа (11-бета-hsd-1) для лечения диабета и ожирения
ATE400271T1 (de) * 2004-07-28 2008-07-15 Hoffmann La Roche Aryl-pyridinderivate als 11-beta-hsd1-hemmer
CA2582276C (en) * 2004-10-04 2011-09-13 F. Hoffmann-La Roche Ag Alkil-pyridines as 11-beta inhibitors for diabetes

Also Published As

Publication number Publication date
UY29457A1 (es) 2006-11-30
WO2006106423A3 (en) 2007-01-04
US20070027118A1 (en) 2007-02-01
NL1031532A1 (nl) 2006-10-10
GT200600134A (es) 2007-01-12
TW200718424A (en) 2007-05-16
WO2006106423A8 (en) 2007-11-08
PE20061357A1 (es) 2007-01-13
WO2006106423A2 (en) 2006-10-12
NL1031532C2 (nl) 2007-03-05

Similar Documents

Publication Publication Date Title
AR056964A1 (es) Derivados de aminosulfonilo, composiciones farmaceuticas y sus usos
AR046767A1 (es) Inhibidores heterociclil amino de 11-beta-hidroxiesteroide deshidrogenasa tipo 1
CO6260076A2 (es) Derivados de uracilo o timina para el tratamiento de la hepatitis c
AR060533A1 (es) Compuestos fenil amido heterociclicos condensados
AR060401A1 (es) Derivados de cromen-2-ona
AR116978A1 (es) Fungicidas de tolilo sustituido
AR044514A1 (es) Acidos carboxilicos alfa sustituidos como moduladores ppar
AR039659A1 (es) Inhibidores de metaloproteinasa de heteroariloxi-aril-espiro-pirimidina-2,4,6-triona n-sustituida metaloproteinasa
AR048669A1 (es) Derivados biciclicos de bisamida
AR057954A1 (es) Compuestos derivados de acido tartarico, composiciones farmaceuticas que los contienen y usos como agentes antimicrobianos.
AR039665A1 (es) Fenilacetamidas sustituidas y su uso como activadores de glucoquinasa
AR073498A1 (es) Derivados de tieno [2-3-d] pirimidin
AR065811A1 (es) Derivados de 2-amino-4h-imidazol-4-ona,composiciones farmaceuticas que los contienen y usos para el tratamiento de la enfermedad de alzheimer y otros trastornos neurodegenerativos.
AR038536A1 (es) N-aril-2-oxazolidinona-5- carboxamidas y sus derivados
PE20050747A1 (es) Pirimidinas herbicidas
AR054560A1 (es) Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer
AR059458A1 (es) Arildihidroisoquinolinonas sustituidas con azaciclilo, procedimiento para su preparacion y su uso como medicamentos
AR058287A1 (es) Derivados de isoquinolina y composicion farmaceutica
AR094496A1 (es) Compuestos tetracíclicos sustituidos con heterociclo y métodos de uso de los mismos para el tratamiento de enfermedades víricas
AR051469A1 (es) Derivados de indol tetraciclicos como agentes antiviricos
RU2010102529A (ru) Способ борьбы с вредителями животных
AR088449A1 (es) Benzilindazoles sustituidos
PE20181094A1 (es) Derivados heterociclicos condensados sustituidos por 2-(het)arilo como pesticidas
CL2012000999A1 (es) Compuestos derivados de pirazoloespirocetona sustituida, inhibidores de acetil-coa carboxilasa; composicion farmaceutica que los comprende; uso para tratar o retrasar la progresion o el inicio de diabetes tipo 2, higado graso no alcoholico (hgna) o la resistencia hepatica a la insulina.
AR052458A1 (es) Amino-imidazolonas para la inhibicion de beta-secretasa

Legal Events

Date Code Title Description
FB Suspension of granting procedure